Shanghai Kehua Bio-EngineeringLtd Valuation

Is 002022 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002022 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 002022's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 002022's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002022?

Key metric: As 002022 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 002022. This is calculated by dividing 002022's market cap by their current revenue.
What is 002022's PS Ratio?
PS Ratio	1.8x
Sales	CN¥1.87b
Market Cap	CN¥3.39b

002022 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.9x
Enterprise Value/EBITDA	-26.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 002022's PS Ratio compare to its peers?

The above table shows the PS ratio for 002022 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	14.8x
300149 ChemPartner PharmaTechLtd	3.3x	n/a	CN¥3.3b
000518 Jiangsu Sihuan Bioengineering	17.1x	n/a	CN¥3.6b
000504 Landfar Bio-medicine	27.2x	n/a	CN¥3.4b
300204 Staidson (Beijing) BioPharmaceuticals	11.6x	n/a	CN¥4.1b
002022 Shanghai Kehua Bio-EngineeringLtd	1.8x	n/a	CN¥3.4b

Price-To-Sales vs Peers: 002022 is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (14.8x).

Price to Sales Ratio vs Industry

How does 002022's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
603716 Thalys Medical Technology Group	1x	n/a	US$256.62m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 002022 is good value based on its Price-To-Sales Ratio (1.8x) compared to the CN Biotechs industry average (7.6x).

Price to Sales Ratio vs Fair Ratio

What is 002022's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002022 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002022's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

-1.8%

13.3%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

-3.1%

-24.5%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

-1.8%

12.8%